SEC Form 4 · accession 0001209191-16-144613
Fulgent Genetics, Inc. · FLGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yun Yen
Director
Period of report
Sep 30, 2016
Accepted (ET)
Oct 4, 2016 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674930
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Predecessor Class D Voting Common UnitsF1,F2 | Sep 30, 2016 | D | 4,000,000 | — | D | 0 | D | |
| Issuer Common StockF3 | Sep 30, 2016 | A | 526,315 | — | A | 526,315 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.
- F2The securities were disposed of and cancelled in the Reorganization in exchange for 526,315 shares of the Issuer's common stock.
- F3The securities were received in the Reorganization in exchange for the cancellation of 4,000,000 of the Predecessor's Class D voting common units.